Creo Medical GroupCMEOF 53 Days Payable is 325.04 as of Dec. 2025, which is 11% above its 10-year median of 294.03. GuruFocus rates CMEOF with a GF Score™ of 53/100 and a GF Value™ of $0.25. The stock has 6 warning signs investors should review. Among 796 Medical Devices & Instruments companies, Creo Medical Group ranks better than 89.45% on this metric.
The historical rank and industry rank for Creo Medical Group's Days Payable or its related term are showing as below:
CMEOF'
s Days Payable Range Over the Past 10 Years
Min: 80.62 Med: 294.03 Max: 32895.63
Current: 317.69
During the past 11 years, Creo Medical Group's highest Days Payable was 32895.63. The lowest was 80.62. And the median was 294.03.
CMEOF's Days Payable is ranked better than 89.45% of 796
companies
in the Medical Devices & Instruments industry
Industry Median: 68.14
vs CMEOF: 317.69
Creo Medical Group's Days Payable
declined
from Dec. 2024 (444.75) to Dec. 2025 (325.04).
It may suggest that Creo Medical Groupaccelerated paying its suppliers.
Creo Medical Group Days Payable Related Terms
Creo Medical Group Days Payable Historical Data
* Premium members only.
The historical data trend for Creo Medical Group's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Creo Medical Group's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Creo Medical Group Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Creo Medical Group's Days Payable distribution charts can be found below:
* The bar in red indicates where Creo Medical Group's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Creo Medical Group's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Creo Medical Group (CMEOF) has a Days Payable of 325.04 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Creo Medical Group and its competitors. This is 11% above median its historical median of 294.03. Over the past decade, Creo Medical Group's Days Payable has ranged from 80.62 to 32,895.63. According to the industry distribution chart, Creo Medical Group ranks #84 out of 796 companies in the Medical Devices & Instruments industry, placing it in the top 10.6%.
Is Creo Medical Group's Days Payable too high?
Creo Medical Group's current Days Payable of 325.04 is 11% above median its 10-year median of 294.03. Over the past 10 years, this metric has ranged from a low of 80.62 to a high of 32,895.63. The Medical Devices & Instruments industry median Days Payable is 68.14. Creo Medical Group's value of 325.04 is 377% above this industry median. Based on the distribution chart, Creo Medical Group ranks #84 out of 796 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Creo Medical Group has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Creo Medical Group's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Creo Medical Group ranks #84 out of 796 companies for Days Payable. This places Creo Medical Group in the top 11% of its industry — outperforming the majority of peers. The industry median Days Payable is 68.14. Creo Medical Group's value of 325.04 is 377% above this benchmark. Historically, Creo Medical Group's own Days Payable has ranged from 80.62 to 32,895.63 over the past decade. While the company's 10-year median is 294.03 vs. the industry median of 68.14, Creo Medical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.14, based on 796 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Creo Medical Group's current Days Payable of 325.04 is 377% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Creo Medical Group and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Creo Medical Group's current Days Payable is 325.04, which is 11% above median its own 10-year median of 294.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creo Medical Group stock overvalued right now?
Creo Medical Group (CMEOF) has a current Days Payable of 325.04. The stock's GF Value™ is $0.25, compared to a current price of $0.20 — trading 20% below its estimated fair value. The current Days Payable is 325.04, which is 11% above median its 10-year median of 294.03 and 377% above the Medical Devices & Instruments industry median of 68.14. Creo Medical Group's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Creo Medical Group (CMEOF), the current Days Payable is 325.04 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Creo Medical Group (CMEOF) Overvalued in 2026?
Based on GuruFocus' analysis, Creo Medical Group stock appears to be undervalued.
The current stock price of $0.20 is trading 20% below its estimated GF Value™ of $0.25.
Key valuation signals for CMEOF:
Days Payable: 325.04 (11% above median its 10-year median of 294.03)
GF Value™: $0.25 vs. price of $0.20 (20% below fair value)
Industry Position: 377% above the Medical Devices & Instruments median (#84 of 796)
No single metric tells the full story. See the CMEOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from United Kingdom and the rest from Europe and the rest of the world.
53GF Score
Get the complete analysis for CMEOF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMEOF has been successfully added to your 
